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ABSTRACT
Activation of macrophages and other immune components to release a series of proinflammatory cytokines
is one of the first events in innate resistance to intracellular infections. Severe manifestations of tuberculosis
(TB) could be caused by alterations in the balance of these cytokines. In this study, lymphokine-activated
killer (LAK) cells of TB patients and normal individuals were generated by stimulation with cytokines in vitro.
The LAK cells of both groups were further triggered with allogeneic tumor targets. Cytokines interferon-g
(IFN-g), tumor necrosis factor-a (TNF-a), and granulocyte-macrophage colony-stimulating factor (GM-CSF)
were estimated in the supernatants generated in the two groups. The aim was to see if infection with TB in-
fluenced the secretory capacity of the immune cells in vitro. Reduced cytokine profiles were observed in TB
patients, indicating defective interactions between patient effector cells with allogeneic transformed cells com-
pared with normal individuals. Partial restoration of IFN-g production was seen with a combination of cy-
tokines interleukin-2 (IL-2) and IL-12 in TB patients. Based on the in vitro observations, we hypothesize that
in vivo also there is diminished immune cell activation of effector cells in response to the presence of infected
macrophages. This probably leads to a diminished secretory function that can be corrected by the use of such
cytokines as IL-2 and IL-12. The effector populations of TB patients are probably in a state of target-induced
anergy, allowing the bacteria to thrive, and immunomodulatory cytokines that improve the host immune re-
sponse toward countering mycobacterial infection.
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TUBERCULOSIS (TB) REMAINS AN IMPORTANT CAUSE of mor-bidity and mortality worldwide, with one third of the pop-
ulation infected with the tubercle bacillus.(1) By far the most
important factor that determines whether infection will ulti-
mately lead to disease is the adequacy of the host immune re-
sponse in general and the cell-mediated immune response in
particular. Proof of this lies in the fact that the risk of TB is
linked to cellular immunodeficiency conditions associated with
age, immunosuppressive drugs, and other diseases, such as di-
abetes, malignancies, silicosis, renal failure, and most notably
AIDS.(2) For a successful protective immune response, the net-
work involving infected macrophages, activated T lympho-
cytes, activated natural killer (NK) cells, and their respective
cytokines needs to be well coordinated.(3) The recent outbreak
of multidrug-resistant TB underscores the need for novel ap-
proaches to treat and prevent TB, including the use of im-
munotherapeutic modalities that enhance the antimycobacterial
defense. Development of such strategies requires a detailed
study of the cytokines that mediate resistance toward TB.(4,5)
Macrophage interleukin-12 (IL-12) production was shown to
be prominent in tuberculous lymph nodes, and it is known that
IL-12 is a central initiator of the local Th1 response,(6) as it is
responsible for induction of interferon-g (IFN-g), tumor ne-
crosis factor-a (TNF-a), granulocyte-macrophage colony-stim-
ulating factor (GM-CSF), IL-3, IL-8, and IL-2 cytokines from
T and NK cells.(7–9) It is known that in vitro culture of human
peripheral blood lymphocytes (PBL) in IL-2 results in the gen-
eration of cytotoxic cells that lyse autologous and allogeneic
tumor targets through release of a number of well-characterized
slow-acting cytokines, such as natural killer cytotoxic factor
(NKCF), IFN, TNF, and lymphotoxin, that are cytostatic or cy-
totoxic for tumors. This has been referred to as the lymphokine-
activated killer (LAK) phenomenon, with NK cells being the
major contributors to LAK activity.(10–15) Similarly, it is pos-
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sible that infected monocytes likewise initiate a cascade of cy-
tokine release from the LAK cells generated in vivo under in-
fectious conditions through release of such cytokines as IL-2.
On the basis of this model, experiments were designed to see
if the potential problem in the host immune response of the TB
patient was a defect in the trigger of important cytokines by the
patient’s LAK cells. The allogeneic cell line U937 served as a
tumor target model to trigger the LAK cells generated in vitro
in the patient group and was compared with LAK cells of nor-
mal individuals. As human infection with Mycobacterium tu-
berculosis displays a spectrum of manifestations that reflect the
efficacy of the immune response,(16) understanding the mech-
anisms of LAK cell-mediated cytokine secretions in vitro will
provide an insight into how the production of cytokines may
be regulated in vivo.
LAK cells were generated by the method of Grimes and
Hersh’s group.(17) Eight patients smear and culture positive for
TB and eight normal individuals (25–50 years of age) were in-
cluded in the study. Peripheral blood mononuclear cells
(PBMCs) from both groups were obtained by the standard Fi-
coll-Hypaque (Sigma Chemical Co., St. Louis, MO) density
gradient centrifugation method and adjusted to 103 106
cells/ml in complete RPMI 1640 culture medium supplemented
with 5% heat-inactivated fetal bovine serum (FBS), 2 mM glu-
tamine, 5 mM HEPES, 5 3 1025 M 2-ME, 100 U/ml penicillin,
and 20 mg/ml gentamicin at pH 7.2–7.4 (Sigma Chemical Co.).
PBMC (2.53 106) were cultured in 12-well tissue culture
plates (Costar, Cambridge, MA) in complete RPMI medium in
the presence of IL-2 (100 U/106 cells), IL-12 (50 U/106 cells),
and IL-2 1 IL-12 (50 U 1 10 U/106 cells) for 3 days at 37°C
in a humidified 5% CO2 atmosphere. rIL-2 was purchased from
Genzyme (Cambridge, MA), and rIL-12 was a kind gift from
G. Trinchieri (Philadelphia, PA). At the end of the incubation
period, nonadherent cells and the supernatants were collected
and centrifuged at 1800 rpm. The supernatants were gently as-
pirated and stored at 270°C in small aliquots, taking care to
avoid repeated freeze-thaw cycles.
After removal of the supernatants of the LAK cells, the ef-
fector cells (E) were thoroughly washed and resuspended in
complete medium. They were then mixed with 5 3 106 U937
cells (tumor target cell line [T] obtained from the National Fa-
cility for Animal Tissue and Cell Culture, DBT, Pune, India).
The E:T ratio was maintained at 1:2, and the mixture was in-
cubated for a further period of 18 h. The mixed population was
harvested, and the supernatants were gently collected and stored
at 270°C in small aliquots. Appropriate controls were main-
tained.
The LAK supernatants collected before and after cocultur-
ing with tumor targets were analyzed by enzyme-linked im-
munosorbent assay (ELISA) for the presence of the cytokines
IFN-g, TNF-a, and GM-CSF according to the standard proto-
col using ELISA reagents (Endogen, Boston, MA). The results
were analyzed using Student’s t-test.
In Figure 1, cytokine production by LAK cells in normal in-
dividuals and TB patients is illustrated. IL-2 and IL-12 were
potent inducers of IFN-g, producing 50006 2000 pg/ml and
80006 2000 pg/ml IFN-g, respectively, in normal individuals.
IL-12 appears to be more potent than IL-2, and the two cyto-
kines together further enhance the production of IFN-g, up to
130006 6500 pg/ml in normal individuals, compared with ei-
ther of them alone (p , 0.01). In the case of TB patients, IFN-
g levels in response to IL-2 and IL-12 were around 40006 2000
and 70006 1000 pg/ml, respectively. The IFN-g level was
80006 1000 pg/ml in response to the two cytokines together.
These results indicate that TB patients also produce IFN-g in re-
sponse to IL-2/IL-12 stimuli, but the levels of IFN-g were sig-
nificantly reduced (p, 0.05) compared with normal individuals.
It was found that in normal individuals, an average of 8000 pg/ml
IFN-g was produced in response to prestimulation with IL-2
alone, and 16,000 pg/ml was produced in response to IL-21 IL-
12, but when IL-12 alone was used, the response was not so dra-
matic. The levels dropped to 2500 pg/ml, indicating that by it-
self IL-12 was unable to prestimulate the cells to produce IFN-g
in response to the target cells. Similarly, TB patients also showed
reduction in IFN-g levels when triggered with tumor targets when
prestimulated with IL-12 alone. IL-2 also failed to prestimulate
the cells to produce IFN-g in response to tumor targets, in con-
trast to normal individuals. However, the response to a combi-
nation of IL-2 and IL-12 was found to be 7000–9500 pg/ml. The
results indicated that there was a significant reduction in cyto-
kine secretion by TB patients in response to tumor targets, com-
pared with normal individuals (p, 0.001). It follows that IL-2
and IL-12 are potent inducers of IFN-g, acting in a synergistic
manner. Patients respond well to a combination of IL-2 and IL-
12 prestimulation, although the response was significantly less
than that in normal individuals. IFN-g production is probably one
of the most physiologically relevant functions of IL-12, and many
of IL-2 in vivo effects are mediated, at least in part, through IFN-
g.(18) It is well known that IL-2 stimulates the secretory activi-
ties of cytotoxic lymphocytes. IL-12 also strongly synergizes with
other stimuli in inducing maximum levels of IFN-g production
and is a known Th1 inducer. These observations have been cor-
roborated in the present study.
The amounts of TNF-a were also compared in both groups
in the same manner as described for IFN-g. As seen in Figure
1, LAK cells produced by three different stimulation conditions
secreted no more than 4206 300 pg/ml of TNF in normal in-
dividuals, whereas in TB patients, the average TNF-a levels in
unstimulated and stimulated cells were around 2000–3500
pg/ml. These results indicate that TB patients produce signifi-
cantly higher levels of TNF-a than do normal individuals (p ,
0.01). On coculturing the prestimulated cells overnight with tar-
get U937 cells at a stimulator/effector ratio of 2:1, there was a
substantial increase in cytokine production in normal individu-
als. It was found that 200–2000 pg/ml TNF-a was produced in
response to prestimulation with IL-2 1 IL-12, but when IL-12
alone was used, the response was not so dramatic. The levels
dropped to 15–90 pg/ml, indicating that by itself IL-12 was un-
able to prestimulate the cells to induce them to produce TNF-
a in response to the target cells. There was, however, no TNF
production in response to tumor targets among the TB patients
even after prestimulation with the cytokines. Therefore, it is
clear that there was a significant reduction in the secretion of
TNF-a by TB patients in response to tumor targets (p , 0.001)
compared with normal individuals. In mycobacterial infection,
TNF-a is required for control of bacillary growth and the pro-
tective granulomatous response, but it may cause an im-
munopathologic condition. Results from experiments using
murine models suggest that the relative amount of TNF-a at
the site of infection determines whether the cytokine is protec-
tive or destructive.(19) TNF-a is even implicated in the syner-
gism between M. tuberculosisand HIV infection.(20,21) The role
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of TNF-a is intriguing and needs to be further investigated be-
fore the complexities of the web of cytokine regulation of T
cell function can be untangled.
GM-CSF was assessed in the same fashion as IFN-g and
TNF-a. As seen in Figure 1, LAK cells produced by three dif-
ferent stimulations secreted around 2500 pg/ml GM-CSF in nor-
mal individuals and no more than 50–500 pg/ml in TB patients
(p , 0.05–0.01). On coculturing the prestimulated cells
overnight with target U937 cells at a stimulator:effector ratio
of 2:1, there was a substantial increase in cytokine production
in normal individuals compared with the LAK values (p ,
0.01). It was found that 200–2000 pg/ml GM-CSF was pro-
duced in response to prestimulation with IL-2 and IL-12, but
when IL-12 alone was used, the response was not so dramatic.
The levels dropped to 15–90 pg/ml, indicating that by itself IL-
12 is unable to prestimulate the cells to a great extent to induce
them to produce GM-CSF in response to the target cells. There
was, however, no GM-CSF production in response to tumor tar-
gets among the TB patients even after prestimulation with the
cytokines compared with normal individuals (p , 0.001).
Unstimulated PBMCs could not be activated by the allo-
geneic tumor cell line to release cytokines, as seen from the
control values, and target cells did not produce these cytokines
when cultured alone (data not shown).
These data indicate that the interaction between LAK cells
and tumor cells causes a large increase in the production of cy-
tokines with known cytotoxic potential in normal individuals.
However, the secretory functions of effector cells in TB pa-
tients were found to be significantly altered. It is possible that
in vivo also the effector population of TB patients shows di-
minished secretory functions in response to the presence of in-
fected macrophages. Decreased cytokine induction by PBLs in
response to M. tuberculosis infection may lead to diminished
macrophage activation and a more permissive environment for
the bacteria. Patients with active TB manifest reduced activity
at the T cell, monocyte, and NK cell levels compared with nor-
mal individuals. This is probably due to the decreased induc-
tion of cytokines by TB patient cells in response to mycobac-
terial infection.
From these results, one can speculate that the effector pop-
ulations of TB patients are in a state of target-induced anergy
and, hence, do not respond in an appropriate manner. This can,
however, be overcome to a large extent by a combination of
the two cytokines IL-2 and IL-12. Knowledge of the cytokine
response to infectious diseases is important in understanding
the immune basis of the host response.(15) Major players have
emerged, and immunotherapy aimed at manipulating these has
already shown promise.(22–24) The current challenge is to mas-
ter the art of navigating the fine line between protection and
pathology in TB.(25,26)
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FIG. 1. Comparison of cytokine (IFN-g/TNF-a/GM-CSF) production by LAK cells in response to stimulation by different cy-
tokines (control/IL-2/IL-21IL-12/IL-12) in normal individuals and TB patients, respectively. Comparison of cytokine produc-
tion after LAK coculture with U937 target cells in normal individuals and TB patients, respectively (n 5 8). Data are expressed
as mean6 SD for each category. IFN-g production by LAK cells in response to a combination of IL-2 1 IL-12 was significantly
greater compared with each cytokine alone (p , 0.01) and significantly lower in TB patients than in normal individuals (p ,
0.05). In response to tumor targets, the levels were significantly greater in normal individuals than in TB patients (p , 0.001).
TNF-a production by LAK cells in TB patients was significantly higher than in normal individuals (p , 0.01). Coculturing with
tumor targets yielded opposite results, with TB patients showing significantly lower values (p , 0.001). GM-CSF production by
LAK cells in response to three different stimulations in normal individuals was significantly higher than in TB patients (p ,
0.05–0.01). In normal individuals, it increased substantially after LAK coculture with U937 target cells (p , 0.01) and was sig-
nificantly higher compared with levels in TB patients (p , 0.001).
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